Company
MapLight Therapeutics
Setting a New Standard of Care for Brain Disorders
Also known as MapLight Therapeutics, Inc.
- Status
- Operatingas of 2026-09-23Source (opens in a new tab)
- Business model
- B2B
- Legal name
- MapLight Therapeutics, Inc.
- maplightrx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
MapLight Therapeutics is a clinical-stage biopharmaceutical company advancing novel therapies for central nervous system disorders.
Funding snapshot
- Total raised
- $356MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $150M2026-08-13
Funding rounds
- $150 Million Private Placement Financing
- $150M2026-08-13, Company stated
- Round, 2025
- $188M2025-07-18, SEC form D sold, 19 investors
- Round, 2023
- $105M2023-07-05, SEC form D sold, 12 investors
- Round, 2022
- $12M2022-10-25, SEC form D sold, 1 investor
- Round, 2021
- $30M2021-02-23, SEC form D sold, 2 investors
- Round, 2019
- $16M2019-08-23, SEC form D sold, 2 investors
- Round, 2019
- $5M2019-02-22, SEC form D sold, 2 investors
About the company
- Status notes
- Current portfolio company
Loading relationship preview